Abstract: A method of purifying bleed air from an engine heats the bleed air only to an extent necessary for the bleed air to react under catalysis from a noble-metal-based reactor bed, converting the contaminants to filterable form. The contaminants are then removed with a post-treatment filter. A purifier functioning according to the present invention, which heats the bleed air to a temperature no greater than 450° F. which it attains without a combustor, thus releases less heat to adjoining components than a prior-art purifier, and outputs purified air at a lower temperature than does a prior-art purifier, which typically needs to include a combustor. The purified air is sufficiently cool as to be suitable for immediate release into interior compartments occupied by humans or the air conditioning system.

Abstract: An environmental control system includes a catalytic reactor and a post treatment filter for cleaning incoming air, and a vapor cycle system for conditioning the air.

Abstract: An air cleaning system and method employs both particulate and gaseous contaminant removal from a flowing air stream to improve air quality in a selected environmental space. Particulate contaminants are removed by an appropriate filter. Gaseous contaminants such as VOCs, CO, and O3 are removed using a catalyst to oxidize such contaminants. The air stream is selectively heated to provide an adequate catalyst reaction temperature and the heat energy is then recovered by a heat exchanger. Various sensors are employed to monitor flow rate, air composition, temperature and pressure. A controller is programmable to control air quality for either minimizing contaminants or minimizing energy usage required to achieve a selected minimum air quality over a period of time.

Abstract: An air cleaning system and method employs both particulate and gaseous contaminant removal from a flowing air stream to improve air quality in a selected environmental space. Particulate contaminants are removed by an appropriate filter. Gaseous contaminants such as VOCs, CO, and O3 are removed using a catalyst to oxidize such contaminants. The air stream is selectively heated to provide an adequate catalyst reaction temperature and the heat energy is then recovered by a heat exchanger. Various sensors are employed to monitor flow rate, air composition, temperature and pressure. A controller is programmable to control air quality for either minimizing contaminants or minimizing energy usage required to achieve a selected minimum air quality over a period of time.

Abstract: A compound having the general formula and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Abstract: In an aircraft, tap water is filtered, vaporized and injected into a trim line of an environmental control system. Filtering is performed by a reverse osmosis filter. Hot, humidified air leaving the trim line is supplied to a cabin of the aircraft.

Abstract: A filter includes a catalyst for oxidizing NOx to NO2 and an alkaline for adsorbing the NO2.

Abstract: A dynamic logic circuit is implemented which decouples the reset of the output from the reset of the evaluation node. An N-tree logic circuit generates a logical output signal in response to a first set of input signals. The output signal is coupled to a gate of a first n-type field effect transistor (NFET) of a parallel coupled pair of NFET devices. The parallel drains are coupled to an output of the dynamic logic circuit and the parallel sources are coupled to ground. The gate of the second NFET device of the pair is coupled to the junction of a source and drain, respectively, of a series connected p-type field effect transistor (PFET) device, and a third NFET device. The third NFET device has a source coupled to ground, and the PFET device has a drain coupled to a voltage supply. Gates of the PFET device and the third NFET device are connected together and receive a logic signal whereby the output of the dynamic logic circuit may be reset.

Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: Compounds of formula I, and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: Compounds of formula I or I', ##STR1## wherein X and Y are independently selected from hydrogen, halo, and (1-6C)alkoxy;R.sup.1 is selected from(A) (1-6C)alkyl;(B) phenyl and naphthyl or substituted versions thereof;(C) phenyl(1-3C)alkyl and naphthyl(1-3C)alkyl;(D) five- and six-membered heteroaryl rings;(E) heteroaryl(1-3C)alkyl and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I or I' and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropsychiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I or I', or a pharmaceutically acceptable salt thereof are claimed. The invention also relates to novel processes for producing enantiomeric methanoanthracenyl sulfoxides.

Abstract: The present invention concerns the novel use of aryl substituted heterocycles of formula I, set out below, which antagonize the pharmacological actions of one of ent endogenous neuropeptide tachykinins an the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment. Certain novel aryl substituted heterocycles of formula I and novel intermediates for their manufacture are also provided.